PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16249722-3	2005	This study was designed to identify and quantify COX-1 and COX-2 gene expression level in inflamed rat molar pulps after administration of three NSAIDs: Celebrex, Vioxx, and Advil.	Celecoxib	153-161	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
16364481-2	2006	In that study we investigated the effects of post-training intrahippocampal infusion of celecoxib as a COX-2-specific inhibitor on spatial memory retention.	Celecoxib	88-97	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	103-108	
16364481-11	2006	Quantification analyses of the immunostaining of COX-2-containing neurons in the dorsal hippocampus show that celecoxib infusions significantly reduced (P<0.05) COX-2 immunoreactivity for the animals that were tested 3 days after the drug infusion.	Celecoxib	110-119	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	49-54	
16364481-11	2006	Quantification analyses of the immunostaining of COX-2-containing neurons in the dorsal hippocampus show that celecoxib infusions significantly reduced (P<0.05) COX-2 immunoreactivity for the animals that were tested 3 days after the drug infusion.	Celecoxib	110-119	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	164-169	
17220053-4	2006	Six of the new products showed higher percent of inhibition (up to 100 %) compared to the highly selective COX-2 inhibitor celecoxib and the nonselective indometacin (CAS 53-86-1) used as reference compounds.	Celecoxib	123-132	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	107-112	
16150053-1	2005	Recently, we demonstrated that intrahippocampal infusion of the cyclo-oxygenase (COX)-2-specific inhibitor celecoxib impaired spatial memory retention in the Morris water maze.	Celecoxib	107-116	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-87	
16150053-10	2005	Quantification analysis by optical density measurements showed that the celecoxib infusion reduced the immunoreactivity of COX-2-containing neurons in the CA1 area of the hippocampus compared with controls, although this reduction was not significant.	Celecoxib	72-81	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	123-128	
16835711-2	2006	We, therefore, studied the chronic effects of the COX-2 inhibitor, celecoxib, given to ethanol-treated rats.	Celecoxib	67-76	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	50-55	
16384742-0	2006	The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats.	Celecoxib	14-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	37-42	
16418777-8	2006	CA II activity was inhibited by sulfonamide-type COX-2 selective agents celecoxib and JTE-522 similarly to a CA II inhibitor acetazolamide, but not by a methylsulfone-type COX-2 inhibitor rofecoxib.	Celecoxib	72-81	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	49-54	
16273290-1	2005	To assess effects of Celecoxib, selective cyclo-oxygenase (COX)-2 inhibitor, on matrix synthesis by chondrocytes under mechanical stress in vitro.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	42-65	
16454238-3	2005	OBJECTIVE: To determine if COX-2 inhibitors like Celebrex are effective in protecting root resorption associated with orthodontic forces.	Celecoxib	49-57	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-32	
15975708-5	2005	Established neuroblastoma xenografts in nude rats treated with the dual COX-1/COX-2 inhibitor, diclofenac, or the COX-2 specific inhibitor, celecoxib significantly inhibits neuroblastoma growth in vivo.	Celecoxib	140-149	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	114-119	
16093206-1	2005	Celecoxib, a specific COX-2 inhibitor, was recently approved for the treatment of rheumatoid and osteoarthritis, acute pain, familial adenomatous polyposis and primary dysmenorrhea.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
16168238-2	2005	Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents.	Celecoxib	191-200	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	146-168	
16139265-7	2005	Celecoxib has retarded COX-2 expression and delayed ulcer healing.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
15629510-3	2005	In the current study, we investigated the molecular mechanisms underlying the effects of the selective COX-2 inhibitor, celecoxib, and assessed the influence of albumin on its actions.	Celecoxib	120-129	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	103-108	
15626595-6	2005	In contrast, selective COX-2 inhibitors (rofecoxib>>celecoxib>nimesulide>NS 398) were thrombogenic, and abolished THR and rise in 6-keto-PGF(1 alpha) induced by ACE-Is.	Celecoxib	58-67	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
15632379-5	2005	COX-2 gene expression, cell proliferation, and apoptosis were analyzed in ZD, ZR, and ZD rats treated with the COX-2 inhibitors celecoxib and indomethacin.	Celecoxib	128-137	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	111-116	
15862805-1	2005	We investigated the efficacy of celecoxib, a specific cyclooxygenase (COX)-2 inhibitor, on arthritic pathophysiology and confirmed its gastric safety in adjuvant-induced arthritis rats.	Celecoxib	32-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	54-76	
15792784-0	2005	Post-training intrahippocampal infusion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats.	Celecoxib	63-72	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	47-52	
15965713-5	2005	The Celecoxib COX-2 inhibitor reduced RTHR and the number of cells in BAL and lung neutrophils influx of rats treated with LPS.	Celecoxib	4-13	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19	
15492235-6	2004	Treatment of established neuroblastoma xenografts in nude rats with the dual COX-1/COX-2 inhibitor diclofenac or the COX-2-specific inhibitor celecoxib significantly inhibited tumor growth in vivo (P < 0.001).	Celecoxib	142-151	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122	
15297470-6	2004	Although all treatments, including celecoxib, were effective in reducing gastric PGE2 synthesis, administering arthritic rats with ASA resulted in a significant increase in gastric content of aspirin-triggered lipoxin (ATL), a COX-2-derived lipid mediator that regulates proinflammatory responses at the neutrophils/endothelial interface.	Celecoxib	35-44	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	227-232	
15482377-1	2004	Recent in vitro studies, clinical trials and epidemiological studies have suggested possible interactions between aspirin and other cyclo-oxygenase (COX) inhibitors, such as ibuprofen of the COX-2 inhibitors celecoxib and rofecoxib.	Celecoxib	208-217	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	191-196	
15285796-2	2004	In the present study we examined the protective effect of celecoxib, a selective inhibitor of the inducible form of cyclooxygenase (COX-2), on dopamine (DA) cell loss in a rat model of PD.	Celecoxib	58-67	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	132-137	
15553225-1	2004	PURPOSE: We have previously demonstrated that celecoxib, a selective COX-2 inhibitor, reaches the retina following repeated oral administrations and inhibits diabetes-induced vascular endothelial growth factor (VEGF) mRNA expression and vascular leakage in a rat model.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74	
15276874-10	2004	The administration of the selective COX-2 inhibitor celecoxib (10 mg/kg, p.o.)	Celecoxib	52-61	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	36-41	
15193428-8	2004	Surprisingly, IT ketorolac or celecoxib significantly increased spinal COX-2 levels at 1 h post-IT injection (p < 0.05) both in inflamed and non-inflamed rats.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	71-76	
15193428-11	2004	However, spinal COX-2 level was upregulated following IT ketorolac and celecoxib injection.	Celecoxib	71-80	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	16-21	
15285796-10	2004	Therefore, inhibition of COX-2 by celecoxib appears to be able, either directly or through inhibition of microglia activation to prevent or slow down DA cell degeneration.	Celecoxib	34-43	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	25-30	
12671717-6	2003	We have shown that the treatment of hepatocytes in vitro with the selective COX-2 inhibitor, celecoxib, was associated with induction of apoptosis and complete inhibition of cellular proliferation.	Celecoxib	93-102	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	76-81	
15612245-0	2004	Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.	Celecoxib	56-65	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	39-44	
15612245-1	2004	OBJECTIVE: To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS).	Celecoxib	40-49	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	63-68	
15083886-2	2004	METHODS: An in vitro mechanical stimulation model based on the rat osteogenic cell line UMR-106 was developed to investigate glucocorticoid (dexamethasone) and selective COX-2 inhibitor (celecoxib) induced changes in the intracellular calcium concentration ([Ca2+]i) and mitochondrial membrane potential (deltapsi(m)).	Celecoxib	187-196	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	170-175	
14665439-6	2004	Rats were given aspirin or NCX-4016 orally and either vehicle or a selective COX-2 inhibitor (celecoxib) intraperitoneally.	Celecoxib	94-103	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	77-82	
14636300-3	2003	We studied their regulation by COX-2 inhibition with celecoxib.	Celecoxib	53-62	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-36	
12967936-6	2003	(4) Pretreatment with the COX-2 inhibitor celebrex (10 mg kg-1 i.v.)	Celecoxib	42-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	26-31	
12671717-4	2003	This study contrasts and compares the effects of aspirin and celecoxib, inhibitors of COX-1 and COX-2, in rat hepatoma HTC-IR cells.	Celecoxib	61-70	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	96-101	
12618347-7	2003	The selective COX-2 inhibitor, celecoxib (2.5-50 mg/kg) treatment exacerbated MPP(+)-induced decrease in DA.	Celecoxib	31-40	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19	
12644391-16	2003	enhanced the anti-oedema effect of the selective COX-2 inhibitor celecoxib (33 mg kg(-1), i.p.)	Celecoxib	65-74	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	49-54	
12397372-8	2002	The effects of celecoxib on INS-1E cells suggest that PGE(2) and other downstream products of COX-2 may contribute to the regulation of insulin release from the beta-cells.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	94-99	
12464396-5	2003	In contrast, continuous application of celecoxib, selective COX-2 inhibitor, resulted in decreased glycine-induced ion current and increased glutamate-induced ion current.	Celecoxib	39-48	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65	
12083738-6	2002	In arthritic rat stomachs, cyclooxygenase (COX)-2 was also up-regulated, where COX-2 selective inhibitors such as rofecoxib or celecoxib provoked gross lesions, although they caused no damage in normal rats.	Celecoxib	127-136	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-49	
12202939-1	2002	The purpose of this study is to show whether selective (celecoxib) and non-selective (piroxicam) inhibitors of COX-2 can alter the morphological and functional changes after the release of a 24 h complete ureteric obstruction in tissue from solitary rat kidney.	Celecoxib	56-65	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	111-116	
12136686-9	2002	On the other hand, COX-1 De dose plus Celecoxib produced evident gastrointestinal lesions, increased LI and neutrophilia, the same as Indo, pointing out that the gastrointestinal damage is due to COX-1 and COX-2 inhibition.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	206-211	
12485462-8	2002	COX-2 expression was observed in 67% of the DMBA-control group and 20% of both celecoxib-treated groups and was absent in normal mammary glands.	Celecoxib	79-88	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
12083738-6	2002	In arthritic rat stomachs, cyclooxygenase (COX)-2 was also up-regulated, where COX-2 selective inhibitors such as rofecoxib or celecoxib provoked gross lesions, although they caused no damage in normal rats.	Celecoxib	127-136	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84	
11932069-20	2002	While acute treatment with morphine has some analgesic effect on hind limb sparing the selective COX-2 inhibitor, celebrex, has no influence on the pain-related behavioural changes in this model.	Celecoxib	114-122	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
11992649-1	2002	In the present study, we evaluated the effect of Celecoxib, a selective COX-2 inhibitor, in an acute model of lung injury induced by carrageenan administration in the rats.	Celecoxib	49-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77	
11992649-7	2002	Therefore, selective inhibitor of COX-2 such as Celecoxib, offers a therapeutic approach for the management of various inflammatory diseases.	Celecoxib	48-57	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	34-39	
12086401-2	2002	Our previous studies indicated that nimesulide and celecoxib, selective COX-2 inhibitors, show inhibitory effects of intestinal carcinogenesis in azoxymethane-treated rats and mice and in Min mice models.	Celecoxib	51-60	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77	
11782374-14	2002	The combined administration of SC-51 and celecoxib inhibited the COX-2 activity to a greater extent than did either of these agents administered alone.	Celecoxib	41-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70	
11848504-0	2001	Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	29-34	
11848504-1	2001	Recent chemopreventive studies in our laboratories showed that the COX-2 inhibitor, celecoxib, inhibited the induction of mammary cancer by 7,12-dimethylbenz(a)anthracene (DMBA).	Celecoxib	84-93	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	67-72	
11990080-4	2001	Indomethacin (IND), an inhibitor preferentially acting on COX-1, as well as nimesulide (NIM) and celecoxib (CECOX), i.e. respectively preferential and selective inhibitors of COX-2, markedly decreased the antinociceptive activity of ACETA in Randall-Selitto test.	Celecoxib	97-106	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	175-180	
10683192-2	2000	In this study, we have compared the effects of a selective COX-2 inhibitor (celecoxib), a nitric-oxide releasing derivative of naproxen (HCT-3012) and naproxen in a model of wound collagen deposition in the rat.	Celecoxib	76-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
11375891-9	2001	Tumours from animals treated with vehicle or celecoxib expressed significantly elevated levels of COX-2 mRNA in comparison with the adjacent normal mucosa.	Celecoxib	45-54	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	98-103	
11149905-8	2001	Selective inhibition of iNOS activity with L-NIL reduced the circulatory failure and liver injury, while selective inhibition of COX-2 activity with SC58635 reduced the renal dysfunction and liver injury caused by hemorrhagic shock.	Celecoxib	149-156	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	129-134	
10994617-0	2000	Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat.	Celecoxib	41-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69	
11330413-8	2001	In conclusion, celecoxib and rofecoxib at doses causing COX-2 but not COX-1 inhibition did not produce toxic lesions in healthy gastrointestinal mucosa, yielding a broad therapeutic margin.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	56-61	
10994617-3	2000	We assessed the effects of celecoxib (a highly selective COX-2 inhibitor) on key pathophysiologic events in NSAID enteropathy.	Celecoxib	27-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-62	
10855352-10	2000	Celecoxib and rofecoxib showed neutrophilia (5,000/mm3) similar to that presented by indomethacin, but there was no leukocyte infiltration in the gastric mucosa; thus we can consider it a COX-2 selective NSAID (non-steroidal anti-inflammatory drug).	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	188-193	
10667579-4	2000	Our previous study has shown that celecoxib, an inhibitor of COX-2, while sparing COX-1, inhibited azoxymethane (AOM)-induced colon tumorigenesis when administered during both initiation and postinitiation stages, ie., celecoxib administered continuously before, during, and after carcinogen treatment.	Celecoxib	34-43	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	61-66	
10667579-17	2000	Thus, in this model system, the chemopreventive efficacy of celecoxib is dose-dependent when this COX-2 inhibitor is administered during the initiation and postinitiation periods.	Celecoxib	60-69	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	98-103	
10855352-11	2000	CONCLUSION: Dose-dependent administration of celecoxib and rofecoxib as COX-2 inhibitors and non-COX-1 inhibitors, respectively, did not produce toxic injuries on healthy gastrointestinal mucosa, thus providing a broad therapeutic spectre.	Celecoxib	45-54	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77	
10678579-12	2000	Nonselective NSAIDs, for instance aspirin, and selective COX-2 inhibitors such as celecoxib (SC-58635) and NS-398 suppress azoxymethane-induced colon carcinogenesis in rats.	Celecoxib	82-91	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-62	
10678579-12	2000	Nonselective NSAIDs, for instance aspirin, and selective COX-2 inhibitors such as celecoxib (SC-58635) and NS-398 suppress azoxymethane-induced colon carcinogenesis in rats.	Celecoxib	93-101	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-62	
8840961-11	1996	Our finding that SC-58635 significantly suppressed colonic ACF formation and crypt multiplicity strengthens the hypothesis that a selective COX-2 inhibitor possesses chemopreventive activity against colon carcinogenesis.	Celecoxib	17-25	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	140-145	
10674759-7	2000	Administration of the COX-2 inhibitor 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfona mide (celecoxib, marketed as Celebrex) worsens motor, but not cognitive, performance, suggesting that COX-2 induction following traumatic brain injury may play a protective role.	Celecoxib	38-115	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
10674759-7	2000	Administration of the COX-2 inhibitor 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfona mide (celecoxib, marketed as Celebrex) worsens motor, but not cognitive, performance, suggesting that COX-2 induction following traumatic brain injury may play a protective role.	Celecoxib	38-115	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	213-218	
10674759-7	2000	Administration of the COX-2 inhibitor 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfona mide (celecoxib, marketed as Celebrex) worsens motor, but not cognitive, performance, suggesting that COX-2 induction following traumatic brain injury may play a protective role.	Celecoxib	117-126	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
9789085-7	1998	By contrast, celecoxib, a selective COX-2 inhibitor, was anti-inflammatory and analgesic in this model.	Celecoxib	13-22	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	36-41	
9458081-3	1998	Our recent study indicated that celecoxib (SC-58635), a specific COX-2 inhibitor, suppressed colonic aberrant crypt foci formation induced by azoxymethane in rats and led us to investigate more specifically the chemopreventive potential of this compound using colon tumors as end points.	Celecoxib	32-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70	
9458081-3	1998	Our recent study indicated that celecoxib (SC-58635), a specific COX-2 inhibitor, suppressed colonic aberrant crypt foci formation induced by azoxymethane in rats and led us to investigate more specifically the chemopreventive potential of this compound using colon tumors as end points.	Celecoxib	43-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70	
9458081-11	1998	The results of this study provide evidence, for the first time, that a specific COX-2 inhibitor, celecoxib, possesses strong chemopreventive activity against colon carcinogenesis.	Celecoxib	97-106	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	80-85	
33033527-1	2020	Objective: To explore the effect of COX-2 inhibitor celecoxib in combination with metformin on the prevention of Hepatocellular carcinoma (HCC) and the mechanisms involved.	Celecoxib	52-61	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	36-41	
32795152-2	2021	Celecoxib is the pioneer sulfonamide being pyrazole derivative COX-2 inhibitors, which used to treat pain and inflammation; they may also have a role in cancer prevention.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	63-68	
32795152-8	2021	Molecular docking was carried out on COX-2 structures, which revealed that NDP-4011 to NDP-4016 targets allosteric binding site similar to the binding mode of the selective COX inhibitor Celecoxib.	Celecoxib	187-196	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	37-42	
34382102-5	2021	RESULTS: Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2.	Celecoxib	75-84	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	317-321	
34818572-6	2022	Additionally, compound AD732 was a less potent inhibitor of COX-2 in vitro than celecoxib, which may indicate lower potential cardiovascular toxicity.	Celecoxib	80-89	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65	
34382102-9	2021	CONCLUSIONS: While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib.	Celecoxib	89-98	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	123-127	
34177398-2	2021	In the present study, the effect of celecoxib (a selective COX-2 inhibitor) pretreatment on radiation-induced injury to rat brain was studied by means of histopathological staining, evaluation of integrity of blood-brain barrier and detection of the expressions of inflammation-associated genes.	Celecoxib	36-45	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
35121552-5	2022	In addition, compounds 13, 16, 20, 25, and 46 displayed lower IC50 values than celecoxib as a reference drug against COX-2 enzyme; having values of 0.09, 13.87, 32.28, 33.01, and 5.18 nM respectively vs 40.00 nM for celecoxib.	Celecoxib	79-88	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122	
35121552-5	2022	In addition, compounds 13, 16, 20, 25, and 46 displayed lower IC50 values than celecoxib as a reference drug against COX-2 enzyme; having values of 0.09, 13.87, 32.28, 33.01, and 5.18 nM respectively vs 40.00 nM for celecoxib.	Celecoxib	216-225	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122	
33577848-3	2021	This study focused on the impacts of splenomegaly on the development of cirrhosis and assessment of the effects of celecoxib, a selective COX-2 inhibitor, on the splenomegaly and cirrhotic liver.	Celecoxib	115-124	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	138-143	
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Celecoxib	71-80	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	327-332	
33679970-0	2021	Celecoxib-Loaded Electrospun Fibrous Antiadhesion Membranes Reduce COX-2/PGE2 Induced Inflammation and Epidural Fibrosis in a Rat Failed Back Surgery Syndrome Model.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	67-72	
33421527-2	2021	We sought to determine the effective concentration of emodin on chondrocytes and to identify the dosage of emodin that induces a comparable therapeutic effect with the COX-2 inhibitor drug, celecoxib that is currently used to treat OA.	Celecoxib	190-199	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	168-173	
31900051-5	2021	Molecular docking and MD simulation of the complex of B6 with prostaglandin-endoperoxide synthase (PTGS) or cyclooxygenase (COX) showed that B6 occupied celecoxib binding site in COX with high affinity (the binding free energy of the complex with COX-1 was -10.5, and -11.2 kcal/mol with COX-2).	Celecoxib	153-162	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	288-293	
33454504-14	2021	The results were found to be in line with the biological findings as they exerted more favorable interactions compared to that of celecoxib, explaining their remarkable COX-2 inhibitory activity.	Celecoxib	130-139	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	169-174	
33447032-0	2021	Topical Nano-Vesicular Spanlastics of Celecoxib: Enhanced Anti-Inflammatory Effect and Down-Regulation of TNF-alpha, NF-kB and COX-2 in Complete Freund"s Adjuvant-Induced Arthritis Model in Rats.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	127-132	
33447032-14	2021	In the animal model of RA, the celecoxib-loaded spanlastics-containing gel significantly reduced edema circumference and significantly suppressed TNF-alpha, NF-kB and COX-2 levels compared to the niosomes-containing gel, the marketed diclofenac sodium gel, and unprocessed celecoxib-loaded gel.	Celecoxib	31-40	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	167-172	
31306980-7	2019	The administration of COX-2 inhibitors, celecoxib and MPO-0029, significantly alleviated LSS-induced chronic mechanical allodynia and inhibited the mRNA expression of inflammatory mediators such as tnf-alpha, Il-1beta, il-6, and inos.	Celecoxib	40-49	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
33489027-1	2020	Objectives: Celecoxib (CLX), a selective cyclooxygenase-II (COX-2) inhibitor, has been used for management of several inflammatory disorders.	Celecoxib	12-21	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65	
33489027-1	2020	Objectives: Celecoxib (CLX), a selective cyclooxygenase-II (COX-2) inhibitor, has been used for management of several inflammatory disorders.	Celecoxib	23-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65	
31490357-6	2020	In the neonatal rat model of NEC, EP2 antagonist and low dose of COX-2 inhibitor Celecoxib, but not EP1 antagonist, reduced NEC pathology as well as COX-2 mRNA and protein expression.	Celecoxib	81-90	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70	
31490357-6	2020	In the neonatal rat model of NEC, EP2 antagonist and low dose of COX-2 inhibitor Celecoxib, but not EP1 antagonist, reduced NEC pathology as well as COX-2 mRNA and protein expression.	Celecoxib	81-90	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	149-154	
32629287-0	2020	Neuroprotective effect of novel celecoxib derivatives against spinal cord injury via attenuation of COX-2, oxidative stress, apoptosisand inflammation.	Celecoxib	32-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	100-105	
32629287-1	2020	A novel series of celecoxib derivatives were synthesized and evaluated for cyclooxygenase (COX-1/COX-2) inhibitory activities for benefit in spinal cord injury (SCI).	Celecoxib	18-27	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
31928220-8	2020	Beneficial effects of salivectomy in an experimental model of BE were counteracted by PPARgamma antagonist, whereas selective COX-2 inhibitor celecoxib synergistically with pioglitazone reduced severity of esophageal damage and protected esophageal mucosa from reflux.	Celecoxib	142-151	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	126-131	
31539536-4	2019	Here, we show that COX-2 inhibition by celecoxib protects against neuronal injury through suppression of oxidative stress and, in this way, mediates its antidepressant effects.	Celecoxib	39-48	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	19-24	
31231624-11	2019	On the contrary, celecoxib inhibited NF-kappaB phosphorylation and nucleus translocation and increased AQP1 expression through inhibiting COX2 activity.	Celecoxib	17-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	138-142	
30904755-13	2019	The molecular docking study of compounds 2d, 2f, 3c and 3d into COX-2 active site revealed a similar binding mode to celecoxib, explaining their remarkable COX-2 inhibitory activity.	Celecoxib	117-126	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69	
30904755-13	2019	The molecular docking study of compounds 2d, 2f, 3c and 3d into COX-2 active site revealed a similar binding mode to celecoxib, explaining their remarkable COX-2 inhibitory activity.	Celecoxib	117-126	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	156-161	
30782576-3	2019	Also by exploiting the chemical structures of selective and marketed COX-2 inhibitors, celecoxib and SC-558 were used in designing the molecules which are used in the treatment of inflammation and related disorders.	Celecoxib	87-96	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74	
30476507-12	2019	COX-2 inhibition using celecoxib, along with COX-1 inhibition, ameliorated spatial memory impairment, astrocyte activation, and neurodegeneration after HH exposure.	Celecoxib	23-32	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
30870859-2	2019	OBJECTIVE: This study was aimed to evaluate the role of dietary phenol caffeic acid (CA), alone and in combination with selective COX-2 inhibitor celecoxib (CEL) in IR-induced acute renal failure (ARF) in rats.	Celecoxib	146-155	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	130-135	
28024294-3	2017	We aimed to investigate the effects of partial and selective COX-2 inhibition without affecting constitutive COX-1 and basal COX-2 activities by celecoxib on mesenteric artery blood flow (MABF), vascular reactivity, oxidative and inflammatory injuries, and survival in septic rats accomplished by cecal ligation and puncture (CLP).	Celecoxib	145-154	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	125-130	
30242499-1	2018	PURPOSE: The present study investigated the preventive effect of the cyclooxygenase (COX)-2 inhibitor, celecoxib, in 7,12-dimethylbenz[a]anthracene (DMBA)-induced ovarian cancer in a rat model.	Celecoxib	103-112	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-91	
30143947-1	2018	Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA).	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	19-24	
30143947-1	2018	Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA).	Celecoxib	11-14	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	19-24	
28739304-7	2017	Whereas CSA hypertension was maintained after selective COX-2 inhibition by celecoxib, the concomitant BRS reductions were largely eliminated.	Celecoxib	76-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	56-61	
28284805-5	2017	Molecular docking study of potent compounds in the series showed Gscore comparable to celecoxib with similar binding orientation for the COX-2 active site which also corroborates the observed in vitro COX-2 inhibition.	Celecoxib	86-95	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	201-206	
29890922-4	2018	Therefore, we evaluated the disease-modifying effects and the optimal dose of polyesteramide microspheres delivering the COX-2 inhibitor celecoxib in a rat OA model.	Celecoxib	137-146	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	121-126	
29872269-3	2018	The binding affinity of ortho-[18F]fluorocelecoxib to COX-1 and COX-2 enzymes were assessed using the competitor celecoxib.	Celecoxib	41-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69	
29872269-7	2018	Competitive inhibition (blocking) of the tracer uptake of ortho-[18F]fluorocelecoxib in the presence of celecoxib by the COX-2 overexpressed CCA cells and the usual CCA cells gave the IC50 values of 0.5 muM and 46.5 muM, respectively.	Celecoxib	75-84	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	121-126	
29519721-6	2018	A single dose (celecoxib 0.24 mg/kg) provides targeted delivery in chronic constriction injury rats, resulting in significant reduction in the visualized inflammation, infiltration of macrophages, COX-2 and PGE2.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	197-202	
28742266-2	2017	Celecoxib (COX-2 selective inhibitor) (5 mg/kg b.wt) was used as a reference drug.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	11-16	
28054752-9	2017	The data underscore the preferential capacity of selective COX-2 inhibition by celecoxib to mitigate CSA hypertension and consequent alterations in cardiac performance and autonomic balance.	Celecoxib	79-88	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
28979299-2	2017	Coxibs such as celecoxib, rofecoxib, and valdecoxib are introduced as selective COX-2 inhibitors to the market.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	80-85	
28013183-9	2017	Docking study of the synthesized compounds showed similar orientation as celecoxib within the active site of COX-2 enzyme and similar ability to emerge deeply in the additional pocket and binding with Arg513 and His90 the key amino acids responsible for selectivity.	Celecoxib	73-82	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	109-114	
25860026-0	2015	Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.	Celecoxib	20-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	101-106	
27086898-1	2016	In order to target celecoxib which is a COX2 inhibitor, with potentials in the prevention and treatment of colitis and colon cancer, it was formulated as microparticles using the solvent/evaporation method and various pH-dependent Eudragit polymers.	Celecoxib	19-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	40-44	
26441478-2	2015	Celecoxib, a COX-2-selective inhibitor providing decreased gastric injury relative to non-selective NSAIDs, is commonly prescribed.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18	
25687638-7	2015	Furthermore, the protein expression of downstream genes of JNK, including activating-transcription factor (Atf-2), matrix metalloproteinase-13 (MMP-13), and cyclooxygenase (COX-2), were also significantly inhibited by CLX combined with DC as compared with single treatments.	Celecoxib	218-221	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	173-178	
22623379-10	2013	In silico molecular docking studies also showed that Dolastatin 15 and Celecoxib may bind to the active site pocket of Bcl2 , thus revealing the direct target of Dolastatin 15 and Celecoxib apart from binding to COX-2.	Celecoxib	71-80	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	212-217	
24878170-4	2014	We also tested whether MK801-induced hyperlocomotion, a behaviour characteristic of adult polyI:C offspring, is prevented by adolescent treatment with celecoxib, a COX-2 inhibitor that impacts the KP.	Celecoxib	151-160	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	164-169	
24905509-5	2014	RESULTS: Intraperitoneal administrations of the selective COX-2 inhibitor celecoxib (7 mg/kg) as well as preferential COX-2 inhibitors like nimisulide (5mg/kg) and aceclofenac (5mg/kg) attenuated hyperalgesia whereas non-COX-2 selective inhibitors like ibuprofen (40 mg/kg) and indomethacin (10mg/kg) did not.	Celecoxib	74-83	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	58-63	
24446128-5	2014	Some rats were given a COX-2 inhibitor (celecoxib; 10 mg/kg/day) by oral gavage for 28 days.	Celecoxib	40-49	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
24721996-1	2014	Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC).	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18	
24622834-14	2014	Pretreatment with celecoxib, a COX-2 inhibitor, abolished therapeutic effect of ghrelin.	Celecoxib	18-27	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-36	
24135073-8	2014	Test drugs did not modify intestinal COX-1 expression, although they enhanced COX-2, with the exception of celecoxib, which downregulated COX-2.	Celecoxib	107-116	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	138-143	
24932515-3	2014	Thus, the current study aimed at evaluating the effects of two testosterone boosting agents; chrysin, a natural flavone and celecoxib, a selective COX-2 inhibitor, in testicular impairment in rats with adjuvant arthritis, an experimental model of RA.	Celecoxib	124-133	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	147-152	
24811609-6	2014	Unexpectedly, celecoxib reduced COX-2 expression in the kidney.	Celecoxib	14-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	32-37	
24811609-9	2014	CONCLUSIONS: Celecoxib beneficially affects the outcome of renal IRI by lowering the expression of COX-2 and hence reducing oxidative stress and increasing the bioavailability of NO.	Celecoxib	13-22	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	99-104	
25140201-1	2014	OBJECTIVES: This study was carried out to investigate the effects of COX-2 selective inhibitor (Celecoxib) or non-selective COX inhibitor (Ibuprofen) on gastrointestinal motility.	Celecoxib	96-105	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74	
25140201-10	2014	CONCLUSION: The COX-2 selective inhibitor (celecoxib) or non-selective COX inhibitor (ibuprofen) have no effects on gastric or small bowel transit.	Celecoxib	43-52	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	16-21	
24064301-9	2014	Interestingly, inhibition of COX-2 by celecoxib and SC-236 completely abolished the migratory response.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	29-34	
24396349-3	2013	In this study, the effect of celecoxib, a highly-selective COX-2 inhibitor, was investigated on OTM in rats.	Celecoxib	29-38	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
23298270-2	2013	The present study aimed to investigate the possible protective effects of celecoxib [a selective cyclooxygenase (COX-2) inhibitor] and N-omega-nitro-L-arginine methyl ester (L-NAME) [a nonselective nitric oxide synthase (NOS) inhibitor] against global ischemia-reperfusion (IR) induced biochemical and histological alterations in the rat hippocampus.	Celecoxib	74-83	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	113-118	
23975340-7	2013	Moreover, celecoxib (10 mg/kg body weight once a day) was administered to rats for 4 weeks to inhibit the expression of COX-2.	Celecoxib	10-19	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	120-125	
23374535-5	2013	Moreover, since PGE2 could increase NBC, we tested whether short-term treatment with celecoxib, a COX-2 inhibitor (2 weeks, 250 ppm in the diet) could reduce the expression of these markers.	Celecoxib	85-94	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	98-103	
23412444-1	2013	Celecoxib, a selective cox-2 inhibitor, has been shown to prevent the heterotopic ossification following total hip arthroplasty.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
23879003-8	2013	Celecoxib, selective inhibitor for COX-2 failed to induce mucosal lesions and did not affect the mucosal blood flow and IL-1beta concentration in the proximal and distal jejunum.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	35-40	
23220160-8	2013	Airway contractions to ovalbumin were attenuated by the unselective COX inhibitor indomethacin, the selective COX-1 inhibitor FR-122047 and COX-2 inhibitor celecoxib.	Celecoxib	156-165	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	140-145	
21720929-7	2011	DAPM treatment resulted in a dose-dependent increase in proliferation that was abolished by co-treatment with the COX-2-selective inhibitor celecoxib.	Celecoxib	140-149	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	114-119	
22648851-1	2012	OBJECTIVE: To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model.	Celecoxib	87-96	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	127-132	
21584750-3	2012	Celecoxib, a selective COX-2 inhibitor (25 mg/kg/day), was fed in the chow, and animals were killed 8 weeks later.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
22564588-7	2012	A COX II inhibitor, celecoxib (10 mg/kg), was administered between 2 consecutive challenges.	Celecoxib	20-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	2-8	
22564588-12	2012	The COX II inhibitor celecoxib significantly attenuated HPV responses (P < .05) and attenuated the elevated blood concentrations of TxB(2) (P < .05), hydroxyl radicals (P < .01), nitric oxide (P < .05), and COX II mRNA expression (P < .05) after H-R challenge.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-10	
22564588-12	2012	The COX II inhibitor celecoxib significantly attenuated HPV responses (P < .05) and attenuated the elevated blood concentrations of TxB(2) (P < .05), hydroxyl radicals (P < .01), nitric oxide (P < .05), and COX II mRNA expression (P < .05) after H-R challenge.	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	219-225	
22564588-14	2012	COX II inhibitor celecoxib attenuated the HPV responses by reducing TxB(2) release.	Celecoxib	17-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-6	
22387071-9	2012	This osteomyelitis-induced pain behavior was reversed by Celecoxib, a selective COX-2 inhibitor.	Celecoxib	57-66	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	80-85	
21241415-11	2011	When compared with those in rats of pseudo-operation group, the expression of COX-2 mRNA and the level of PGE2 were upregulated in rats undergoing EJA irrespective of H. pylori infection (p < .05) and downregulated in rats treated with celecoxib (p < .05).	Celecoxib	239-248	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	78-83	
21482120-0	2011	Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation.	Celecoxib	73-82	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	52-57	
22060288-6	2011	KEY FINDINGS: COX-2 over-expression during reflux oesophagitis promotes inflammation of the oesophagus as celecoxib pretreatment significantly reduced tissue damage and MPO activity in rats with reflux oesophagitis (RE-rats).	Celecoxib	106-115	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19	
21900596-8	2011	Selective uptake of (18)F-7 was observed in inflamed rat paws compared with the noninflamed contralateral paws and uptake was blocked by pretreatment with the COX-2 inhibitor, celecoxib.	Celecoxib	176-185	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	159-164	
21174079-2	2011	This study investigated whether the selective cyclooxygenase (COX)-2 inhibitor, celecoxib, can upregulate HO-1 expression.	Celecoxib	80-89	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	46-68	
21174079-11	2011	This study demonstrates a COX-2-independent action of celecoxib in upregulating HO-1 in macrophages and VSMCs.	Celecoxib	54-63	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	26-31	
21241415-16	2011	Celecoxib administration attenuates the incidence of EA by inhibiting COX-2 expression.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	70-75	
19949782-1	2010	Our study was designed to investigate the protective effect of the COX-2 inhibitor, celecoxib, on renal tubules against shock wave lithotripsy (SWL).	Celecoxib	84-93	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	67-72	
20600917-11	2010	Taken together, our results suggest that the sulphonamide group in the structure of celecoxib is more critical for the development of hypoalgesia in our model than its ability to inhibit COX-2.	Celecoxib	84-93	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	187-192	
19949782-4	2010	The COX-2 group was administered celecoxib (10 mg/kg).	Celecoxib	33-42	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9	
19949782-15	2010	However, the COX-2 gene expression was significantly increased in the control group, which was prevented by celecoxib in COX-2 group.	Celecoxib	108-117	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18	
19949782-15	2010	However, the COX-2 gene expression was significantly increased in the control group, which was prevented by celecoxib in COX-2 group.	Celecoxib	108-117	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	121-126	
20219444-3	2010	In addition, we examined effects of administration of a COX-2 inhibitor, celecoxib, on neuroblast differentiation.	Celecoxib	73-82	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	56-61	
19918950-8	2010	COX-2 expression in PAIII cells was downregulated by Celecoxib and Selenocoxib-1 at 20 and 5 microM, respectively; the COX-2 activity was, however, not affected by Selenocoxib-1.	Celecoxib	53-62	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
19356723-1	2009	Recent clinical trails reported that adjunctive cyclooxygenase (COX)-2 inhibition with celecoxib is beneficial in treating depression.	Celecoxib	87-96	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	48-70	
19666045-8	2009	Rofecoxib and celecoxib (both selective COX-2 inhibitors) also reversed the perphenazine-induced oxidative stress.	Celecoxib	14-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	40-45	
19041231-1	2009	Selective COX-2 inhibitor, celecoxib, delays the healing of gastric ulcers by inhibiting prostaglandins synthesis.	Celecoxib	27-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	10-15	
20361677-1	2009	OBJECTIVE: To compare the preventive effect of dietary and topical Celecoxib (CCB), a potent inhibitor of COX-2 on 4-NQO-induced tongue SCC in rat.	Celecoxib	67-76	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	106-111	
20361677-1	2009	OBJECTIVE: To compare the preventive effect of dietary and topical Celecoxib (CCB), a potent inhibitor of COX-2 on 4-NQO-induced tongue SCC in rat.	Celecoxib	78-81	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	106-111	
19798548-0	2009	The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats.	Celecoxib	15-24	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	28-33	
19798548-4	2009	Celecoxib, a selective COX-2 inhibitor, in doses of 3, 5, 10, and 15 mg/kg was effective in reducing paw edema in irradiated and non-irradiated rats in a dose-dependent manner as well as diclofenac (3 mg/kg), a non-selective COX inhibitor.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
19356723-7	2009	Chronic treatments with celecoxib alleviated the depressive-like behavior and reversed the levels of COX-2 expression and PGE2 concentration in stressed rat in a dose-dependent manner.	Celecoxib	24-33	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	101-106	
19356723-8	2009	Celecoxib also improved the emotional state and decreased COX-2 expression and PGE2 concentration in naive rats.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	58-63	
19356723-9	2009	In addition, a single dose of celecoxib treatment reversed COX-2 expression and PGE2 concentration, but didn"t alter the depressive-like behavior in stressed rat.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
19356723-11	2009	Furthermore, these data indicate that chronic celecoxib treatment reverse chronic unpredictable stress-induced depressive-like behavior might via reducing COX-2 enzyme in brain, and the selective COX-2 inhibitors could be developed as potential remedies for the management of depression.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	155-160	
20225762-2	2009	Indeed, one of the specific COX-2 inhibitors, celecoxib, had been accepted by the US FDA for the treatment of familial adenomatous polyposis.	Celecoxib	46-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	28-33	
19233864-6	2009	In addition, the ATPgammaS-stimulated cPLA2 expression was inhibited by U0126, SB202190, helenalin, celecoxib (a selective COX-2 inhibitor), and PGE2 receptor antagonists (AH6809, GW627368X, and SC-19220).	Celecoxib	100-109	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	123-128	
19505386-6	2009	The present study attempts to identify the effects on DMBA-induced tumor growth (a) of diets rich in fat and (b) of the highly selective COX-2 inhibitor Celecoxib, which has been claimed to offer substantial protection against carcinogenesis.	Celecoxib	153-162	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	137-142	
18819100-9	2009	Selective COX-2 inhibitor celecoxib at a dose of 500 mg/kg/bw administered for 52 weeks reduced infiltrating monocytes, inhibited iNOS, NF-kappaB p65 expression, induced apoptosis and tumor growth inhibition.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	10-15	
19247274-3	2009	Rats fed HFD ad libitum were further divided into three subgroups co-treated with vehicle (HFa), or a selective COX-2 inhibitor celecoxib (HFa-Cel) or mesulid (HFa-Mes).	Celecoxib	128-137	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	112-117	
18435714-9	2009	Although celecoxib was sufficient in suppressing the cyclo-oxygenase (COX)-2 expression in the control organ (kidney), it failed to suppress the enhanced hepatic COX-2 expression.	Celecoxib	9-18	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	53-76	
19090909-3	2008	Herein, the aim of this study was to evaluate the action of anti-COX-2 selective drug (celecoxib) on bone repair associated with laser therapy.	Celecoxib	87-96	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	65-70	
18823975-1	2008	Pretreatment using celecoxib, a cyclooxygenase (COX) 2 inhibitor, or indomethacin, a nonselective COX inhibitor, reduced lypopolyssaccharide (LPS)-induced leukocyte migration to the rat peritoneal cavity.	Celecoxib	19-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	32-54	
18592140-6	2008	COX-2 immunoreactivity of the celecoxib treated specimens was more intense in the first analyzed period, and no longer observed in the periods of 14 and 21 days.	Celecoxib	30-39	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
19066421-2	2008	Indomethacin (IND) and celecoxib (CEX) were used as relatively selective inhibitors of COX-1 and COX-2, respectively.	Celecoxib	23-32	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
19066421-2	2008	Indomethacin (IND) and celecoxib (CEX) were used as relatively selective inhibitors of COX-1 and COX-2, respectively.	Celecoxib	34-37	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
17937934-11	2008	Thus, indomethacin and celecoxib, by inhibiting COX-2, may protect against ECS-induced amnesia.	Celecoxib	23-32	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	48-53	
17937934-12	2008	Furthermore, COX-2 mediated increase in hippocampal kynurenic acid may impair glutamate-dependent learning and memory processes at ionotropic glutamatergic receptor sites; the inhibition of kynurenic acid synthesis by celecoxib and its induction by indomethacin may explain the greater benefits with celecoxib.	Celecoxib	218-227	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18	
17937934-12	2008	Furthermore, COX-2 mediated increase in hippocampal kynurenic acid may impair glutamate-dependent learning and memory processes at ionotropic glutamatergic receptor sites; the inhibition of kynurenic acid synthesis by celecoxib and its induction by indomethacin may explain the greater benefits with celecoxib.	Celecoxib	300-309	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18	
18458699-1	2008	OBJECTIVE: To assess the mechanism of exacerbation of colonic damage in rat colitis model induced by trinitrobenzene sulfonic acid (TNBS) treated with celecoxib (a selective COX-2 inhibitor).	Celecoxib	151-160	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	174-179	
18817354-5	2008	RESULTS: The expression of COX-2 was strong in the model group, significantly lower in the high- and median-dose and the Celecoxib Capsules groups than in the model control (P < 0.01) as well as in the high-dose than in the median- and low-dose groups (P < 0.01).	Celecoxib	121-130	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-32	
18458699-15	2008	CONCLUSION: Selective COX-2 inhibitor-celecoxib could decrease the expression of COX-2 in intestinal tissue, attenuate the inflammatory index of colon tissues of experimental colitis induced by TNBS.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
18458699-15	2008	CONCLUSION: Selective COX-2 inhibitor-celecoxib could decrease the expression of COX-2 in intestinal tissue, attenuate the inflammatory index of colon tissues of experimental colitis induced by TNBS.	Celecoxib	38-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	81-86	
17989504-2	2008	Indomethacin and celecoxib were used as relatively selective inhibitors of COX-1 and COX-2, respectively.	Celecoxib	17-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	85-90	
17720896-4	2007	The effects of a selective COX-2 inhibitor, celecoxib, on these markers were also investigated in diabetic rats.	Celecoxib	44-53	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-32	
17979648-1	2007	Celecoxib, a selective COX-2 inhibitor is commonly used in the treatment of arthritis.	Celecoxib	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28	
17828456-5	2007	The Cox-2 antagonist Celecoxib (3 mg/kg i.p.)	Celecoxib	21-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9	
17828456-9	2007	Cox-2 expression was significantly reduced in both parts of the amygdala in the Celecoxib group.	Celecoxib	80-89	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
17828456-12	2007	This data indicates that inhibition of Cox-2 by Celecoxib is associated with regression of apoptosis in the amygdala following myocardial infarction.	Celecoxib	48-57	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	39-44	
19090241-6	2007	Both selective COX-2 inhibitor (celecoxib) and non-selective COX-2 inhibitor (aspirin) decreased the rigidity of parkinsonian rats p<0.05 but rigidity recovery after administration the selective COX-2 inhibitor was more than non-selective COX-2 inhibitor.	Celecoxib	32-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20	
17604006-11	2007	The inhibitory effects of celecoxib and ibuprofen suggest that PGE(2) was generated via COX-2.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-93	
17646679-7	2007	The evidence supports the conclusion that celecoxib exerts its cytotoxicity towards myocytes through COX-2-independent mediated pathways.	Celecoxib	42-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	101-106	
17112499-6	2007	The specific cyclooxygenase (COX)-2 inhibitors celecoxib (50 mg/kg s.c.) and rofecoxib (25 mg/kg s.c.) did not affect mucosal prostaglandin E2 level, nor did they decrease gastric mucosal blood flow, even when hydrochloric acid was added to the chamber.	Celecoxib	47-56	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-35	
17463161-6	2007	There were no differences in the level of prostaglandin E(2) in these tissues, indicating that celecoxib decreases fat accumulation by down-regulating FAS through a COX-2-independent mechanism.	Celecoxib	95-104	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	165-170	
17364667-3	2007	This study was designed to determine the effects of COX-2 inhibitor (celecoxib) on the migration, proliferation, and types I and III collagen expression of tendon cells intrinsic to rat Achilles tendon.	Celecoxib	69-78	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	52-57	
17268902-2	2007	In this experimental study of bilaterally adrenalectomized (ADX) rats, we aimed to investigate whether the administration of selective (celecoxib) inhibitor of COX-2 would alter the morphological and functional changes in rat kidney tissue.	Celecoxib	136-145	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	160-165	
17268902-7	2007	In group 3 (ADX/COX-2) rats, the same operation was performed as described for group 2 and then the COX-2 inhibitor celecoxib was administered by gavage for a period of 7 days.	Celecoxib	116-125	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	100-105	
20020969-1	2007	ABSTRACT The anticancer efficacy of two different classes of NSAIDs, the nonspecific cyclooxygenase (COX) inhibitor aspirin and the specific COX-2 inhibitor celecoxib, was examined at their therapeutic anti-inflammatory doses during 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis in a rat model.	Celecoxib	157-166	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	141-146	
16920168-8	2006	The SEB-induced neutrophil accumulation in BAL fluid was reduced by pretreatment with dexamethasone (0.5 mg/kg), the COX-2 inhibitor celecoxib (3 mg/kg), the selective iNOS inhibitor compound 1400 W (5 mg/kg) and the lipoxygenase inhibitor AA-861 (200 microg/kg).	Celecoxib	133-142	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122	
17059761-0	2006	[Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].	Celecoxib	52-61	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	36-41	
17059761-1	2006	BACKGROUND &amp; OBJECTIVE: Although we have previously showed that a selective cyclooxygenase-2(COX-2) inhibitor celecoxib prevents gastric cancer development in a rat model of gastric carcinogenesis, the role of celecoxib on gastric premalignant lesions remains unknown.	Celecoxib	114-123	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
17059761-1	2006	BACKGROUND &amp; OBJECTIVE: Although we have previously showed that a selective cyclooxygenase-2(COX-2) inhibitor celecoxib prevents gastric cancer development in a rat model of gastric carcinogenesis, the role of celecoxib on gastric premalignant lesions remains unknown.	Celecoxib	214-223	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	97-102	
16954456-4	2006	COX-2 selective inhibitor celecoxib was given for further investigation of the cardioprotection of EPC.	Celecoxib	26-35	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5	
16437200-1	2006	The purpose of this study was to demonstrate the direct effects of celecoxib, one of the selective cyclo-oxygenase (COX)-2 inhibitors, on nitric oxide (NO) and prostaglandinE2 (PGE2) synthesis in cultured osteoarthritic chondrocyte comparing with those of indomethacin.	Celecoxib	67-76	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	99-122